Patient experiences and access to GLP-1 therapies in NHS Tier 3
Research type
Research Study
Full title
Exploring patients’ experiences and access to GLP-1 and dual GIP/GLP-1 receptor agonists for weight management within an NHS Tier 3 service: a qualitative study
IRAS ID
366841
Contact name
Hala Shokr
Contact email
Sponsor organisation
University of Manchester
Duration of Study in the UK
3 years, 6 months, 31 days
Research summary
Obesity is a major and growing public health concern in the UK, with many adults facing challenges in accessing effective long-term treatment. Recently, anti-obesity medications, including glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, have become increasingly available within NHS Tier 3 weight management services. Despite their expanding use, there is limited empirical evidence exploring patients’ motivations, experiences, and perceptions of these treatments.
This qualitative study aims to explore patients’ experiences of accessing and using weight-loss injectable medications, such as semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro), within NHS Tier 3 services. It will examine access pathways, patient experiences, awareness of risks and benefits, and barriers to treatment. The study will include both individuals currently engaged with services and those who have discontinued, enabling comparison of factors influencing engagement, adherence, and service utilisation.
Interviews will be conducted with adults aged 18 years and over who are using or used GLP-1-based therapies for weight management within NHS Tier 3 services. Participants will be recruited through collaboration with MoreLife UK and Salford Royal NHS Foundation Trust. Each participant will take part in a single interview lasting approximately 50 minutes, conducted in person, online, or by telephone. No clinical procedures or follow-up visits are required.
Findings will provide valuable insights into patient perspectives, supporting healthcare professionals and policymakers in improving service design, promoting equitable access, and ensuring the safe and appropriate use of these medications. This study forms part of a PhD at the University of Manchester.
This study will take place between 01/06/2026 and 31/12/2029.
REC name
Wales REC 4
REC reference
26/WA/0169
Date of REC Opinion
2 Jun 2026
REC opinion
Favourable Opinion